Uniqure NV Announces Clinical Update On Gene Therapy for the Treatment of Huntington Disease Transcript
Good day, and thank you for standing by. Welcome to the uniQure conference call. (Operator Instructions)
Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Maria Cantor, Chief Communications Officer. Ms. Cantor, the floor is yours.
Good morning, and thank you for joining us. This morning, uniQure announced initial observations on the first 4 patients enrolled in the ongoing Phase I/II clinical trial of AMT-130 in Huntington's disease. 2 of these 4 patients received AMT-130, and 2 patients experienced an imitation surgical procedure in this randomized blinded study being conducted in the United States. Early observations shared today relate to safety and tolerability at 12 months following AMT-130 administration. Joining me for this investor event and webcast are Matt Kapusta, our Chief Executive Officer; and Dr. Ricardo Dolmetsch, our President of Research and Development.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |